Quick Listen: Scrip's Five Must-Know Things

Nov 28 2022

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.

Scrip Five Must Know Things — weekly audio roundup of selected insights from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 25 November 2022, including: a preview of the CTAD Alzheimer’s meeting;...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

MBX Surges As Phase II Data Show Competitive Profile For Canvuparatide

Sep 22 2025

• By Mandy Jackson

MBX Biosciences reported Phase II results for once-weekly canvuparatide that showed comparable efficacy to Ascendis Pharma’s once-daily Yorvipath for hypoparathyroidism.

Pfizer Jumps Back Into Obesity With $4.9bn Bid For Metsera

Sep 22 2025

• By Joseph Haas

Months after terminating obesity candidate danuglipron, Pfizer is placing a hefty bet on Metsera and what it calls its highly differentiated incretin/amylin analog candidates.

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

Sep 22 2025

• By Kevin Grogan

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

Sanofi’s Pipeline Pressure Continues As Tolebrutinib Trips Near Finish Line

Sep 22 2025

• By Manas Mishra

Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.

Why India Revoked The Entresto Patent And Novartis Abstained From Proceedings

Sep 22 2025

• By Anju Ghangurde

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.